FDA approves Zegalogue injection to treat diabetic patients with severe hypoglycemia

CompilationFan Dongdong

A few days ago, Zealand Pharma announced that the US FDA has approved Zegalogue (dasiglucagon) injection for the treatment of severe hypoglycemia in children and adult diabetic patients 6 years and older.

The FDA approved Zegalogue based on the efficacy results of three randomized, double-blind, placebo-controlled, multicenter Phase 3 studies in children and adults with type 1 diabetes between 6 and 17 years of age.

The test results showed that compared with placebo (recovery time of 30 to 45 minutes), the blood glucose recovery rate of patients after Zegalogue administration was faster, with an average median recovery time of only 10 minutes.

Severe hypoglycemia in diabetic patients is a serious life-threatening disease, mainly caused by a severe drop in blood sugar levels caused by insulin treatment, and is one of the most worrying complications in diabetes treatment.

Previously, the first aid for hypoglycemia was mainly glucagon.

Reference source: Zealand Pharma Announces FDA Approval of Zegalogue® (dasiglucagon) injection, for the Treatment of Severe Hypoglycemia in People with.